Clinical trials: Infectious Encephalitis
Japanese Encephalitis
Study of a Single Primary Dose Live Attenuated Japanese Encephalitis Chimeric Virus Vaccine (IMOJEV®) in Healthy Subjects
The purpose of this study is to describe the immunogenicity and safety of IMOJEV® in adult and pediatric populations in Vietnam and serve a bridging study to compare immunogenicity, reactogenicity, and safety data obtained with…
- Trial name
- NCT02492165
- Testing
- Live attenuated Japanese encephalitis chimeric virus vaccine (IMOJEV®)
- Where
- Vietnam
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
West Nile Fever
Safety and Immunogenicity Study of ChimeriVax West Nile Vaccine in Healthy Adults
The purpose of this study is to determine if ChimeriVax West Nile vaccine is safe and effective in preventing West Nile disease in adults over 50 years of age.
- Trial name
- WinVax004 (NCT00746798)
- Testing
- ChimeriVax-WN02 vaccine
- Where
- 15 sites in United States
- Volunteers
- 479 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Japanese Encephalitis, Japanese Encephalitis Vaccine
A Prospective, Open Label Study of Human T Cell Responses to Live Attenuated Japanese Encephalitis Vaccine SA14-14-2
Japanese encephalitis (JE) live attenuated vaccine SA14-14-2 has been in use for more more than 20 years in Asia. JE vaccine SA14-14-2 is licensed in India and has been widely used since 2006.
- Trial name
- NCT01656200
- Testing
- Live attenuated Japanese encephalitis vaccine SA14-14-2
- Where
- 2 sites in India
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- Indian Institute of Science
Encephalitis, Japanese Encephalitis
A Study of ChimeriVax™-JE Live Attenuated Vaccine in Healthy Adults
The purpose of this study is to assess the safety, tolerability, immunogenicity, and duration of immunity of one or two doses of ChimeriVax™-JE vaccine separated by 5 or 6 months in adults.
- Trial name
- NCT00981175
- Testing
- Live attenuated Japanese encephalitis virus, then ChimeriVax diluent, ChimeriVax diluent, then Live attenuated Japanese encephalitis virus
- Where
- Australia
- Volunteers
- 202 people, healthy volunteers welcome
- Sponsor
- Sanofi
Encephalitis, Tick-Borne
Immunogenicity, Safety and Interchangeability of Two Tbe Vaccines Administered According to a Conventional Schedule in Children
The objective of this study is to assess the immunogenicity, safety and interchangeability of two different TBE vaccines in children aged 1-11 years, the first and second vaccination with either FSME-IMMUN 0.25ml Junior or…
- Trial name
- NCT00840801
- Testing
- Tick-Borne Encephalitis (TBE) Vaccine (Inactivated)
- Where
- 8 sites in Austria, Czechia
- Volunteers
- 302 people, healthy volunteers welcome
- Sponsor
- Pfizer
Japanese Encephalitis, Measles
Immunogenicity of Japanese Encephalitis Vaccine Co-administered With Measles-Mumps-Rubella Vaccine (MMR)
This is a phase IV, randomized, controlled, open-label study proceed in healthy children aged 8 months in China. The primary objective is to demonstrate the immunogenicity of simultaneous administration of JEV-I and MMR is not…
- Conditions
- Japanese Encephalitis, Measles, Mumps, Rubella
- Trial name
- NCT06331702
- Testing
- Vero cell-drived inactive Japanese encephalitis vaccine, Measles-Mumps-Rubella Vaccine
- Where
- China
- Volunteers
- 408 people, healthy volunteers welcome
- Sponsor
- Liaoning Chengda Biotechnology CO., LTD
Japanese Encephalitis
Immune Response in IXIARO Batch JEV09L37 Recipients Before and After Revaccination
IC51-319 is a single-arm, open-label study that investigates immune responses in subjects undergoing revaccination after receiving the subpotent batch of IXIARO JEV09L37 during primary immunization.
- Trial name
- NCT01559831
- Testing
- IXIARO
- Where
- United Kingdom
- Volunteers
- healthy volunteers welcome
- Sponsor
- Valneva Austria GmbH
Encephalitis, Tick-borne
Safety Study in Volunteers From 16 to 65 Years of Age: FSME IMMUN NEW vs. ENCEPUR
The purpose of this study is to assess the safety of a vaccination schedule consisting of two vaccinations (21-35 days apart) with the tick-borne encephalitis (TBE) vaccine FSME-IMMUN NEW (5 consecutive lots) in comparison to…
- Trial name
- NCT00161824
- Testing
- Tick-Borne Encephalitis (TBE) Vaccine (Inactivated)
- Where
- 7 sites in Poland
- Volunteers
- 3,800 people, healthy volunteers welcome
- Sponsor
- Pfizer
Tick Borne Encephalitis
Evaluation of Immunogenicity of Different Tick Borne Encephalitis (TBE) Fast Protective Traveler Schemes With Inactivated TBE Whole Virus Vaccine
The study aims to answer this question: whether adequate immunity can be achieved in a short time, that is, by a rapid immunisation process, using at least one of 3 new TBE immunisation schedules? The investigators will test the…
- Trial name
- immunisation (NCT00890422)
- Testing
- FSME vaccination (FSME-Immun)
- Where
- 2 sites in Austria, Czechia
- Volunteers
- 99 people, healthy volunteers welcome
- Sponsor
- Elisabethinen Hospital
Japanese Encephalitis
Long Term Immunity and Safety Following Vaccination With the JEV IC51 (IXIARO®, JESPECT®) in Pediatric Population In Non Endemic Countries. Uncontrolled, Ph3 FU-Study
The study investigates long-term immunity and safety of IC51 (IXIARO®, JESPECT®) in a pediatric population vaccinated in the parent study IC51-322.
- Trial name
- NCT01246479
- Testing
- Blood draw, IC51 has given in the parent study IC51-322
- Where
- 5 sites in United States, Australia and 1 more
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- Valneva Austria GmbH
Encephalitis, Encephalitis, Viral
Efficacy and Safety of Calculus Bovis Sativus (CBS) for Adult Encephalitis (CBSinEncephalitis)
Based on the records of traditional Chinese medicine, CBS has the functions of purifying the heart, eliminating phlegm, stimulating bile secretion, and soothing the nerves.
- Conditions
- Encephalitis, Encephalitis, Viral, Autoimmune Encephalitis Caused by N-Methyl D-Aspartate Receptor Antibody, Autoimmune Encephalitis
- Trial name
- NCT06584045
- Testing
- Calculus bovis sativus (CBS)
- Where
- China
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- Tongji Hospital
Encephalitis, Japanese
Long-term Immunogenicity After Receipt of JE Vaccine and Antibody Response and Safety to a Booster Dose
This study aims to understand the persistence of the Japanese encephalitis (JE) antibody response in previously vaccinated children.
- Trial name
- NCT02514746
- Testing
- Live Attenuated Japanese Encephalitis SA-14-14-2 Vaccine
- Volunteers
- 561 people, healthy volunteers welcome
- Sponsor
- PATH
Japanese Encephalitis
Comparison of Three Commercial Batches of the Japanese Encephalitis Vaccine IC51
The objective is to demonstrate equivalence of three commercial IC51 batches in terms of geometric mean titers for anti-JEV neutralizing antibody
- Trial name
- NCT00595465
- Testing
- Japanese Encephalitis purified inactivated vaccine
- Where
- 4 sites in Austria, Germany
- Volunteers
- 389 people, healthy volunteers welcome
- Sponsor
- Valneva Austria GmbH
Japanese Encephalitis
Safety Observation of the Japanese Encephalitis Vaccine Given With a Primary Immunization
This is a single-arm, non-randomized, open-label post-marketing safety observation study. The purpose of this study is to investigate the safety of JEV-I given with primary immunization in a large amount of healthy children aged…
- Trial name
- NCT06372665
- Where
- China
- Volunteers
- 15,357 people, healthy volunteers welcome
- Sponsor
- Liaoning Chengda Biotechnology CO., LTD
Japanese Encephalitis
Flavivirus Cross-priming Potential of IMOJEV
There is a pressing need for a better experimental system to understand flavivirus antibody responses, beyond dengue, to make sure the investigators are using current vaccines to greatest effect and to inform the development of…
- Trial name
- FlaviPrime (NCT03920111)
- Testing
- IMOJEV
- Where
- United Kingdom
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- University of Liverpool
Japanese Encephalitis
Effect of a Booster Dose of the Japanese Encephalitis Vaccine IC51
The objective is to assess the effect of a booster vaccination on immunogenicity of IC51 in terms of seroconversion rate.
- Trial name
- NCT00595309
- Testing
- IC51
- Where
- 3 sites in Austria, Germany
- Volunteers
- 198 people, healthy volunteers welcome
- Sponsor
- Valneva Austria GmbH
Encephalitis, Tick-borne
Safety and Immunogenicity Study of 3 Vaccinations With TICOVAC in 2 Dosages in Healthy Children Aged Between 6 Months and 3 Years
The purpose of this study is to evaluate a) whether the seroconversion rates in children are equivalent after two and/or three partial vaccinations with TICOVAC 0.25 mL and TICOVAC 0.5 mL, and b) whether there is a difference in…
- Trial name
- NCT00161746
- Testing
- Tick-Borne Encephalitis (TBE) Vaccine (Inactivated)
- Where
- 7 sites in Austria
- Volunteers
- healthy volunteers welcome
- Sponsor
- Pfizer
Rabies, Japanese Encephalitis
Evalution of Immunogenicity, Safety and Booster Response of a Rabies Vaccine Administered Concomitantly With Japanese Encephalitis Vaccine in Toddlers
This study evaluated the safety and immunogenicity of rabies vaccine and Japanese encephalitis vaccine in toddlers. All children developed adequate immune responses.
- Conditions
- Rabies, Japanese Encephalitis, Pre-Exposure Prophylaxis
- Trial name
- NCT00694460
- Testing
- Three 1 mL doses of Rabies vaccine and two JE vaccine, Three 0.5 mL doses of Rabies vaccine and two JE vaccine, Three 0.1mL doses of Rabies Vaccine and two JE vaccine
- Where
- Thailand
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Novartis
Japanese Encephalitis
Safety and Tolerability of the Japanese Encephalitis Vaccine IC51
The objective is to investigate the safety and tolerability of Japanese Encephalitis vaccine IC51 with an inactive control in healthy subjects aged > or = 18 years
- Trial name
- NCT00605085
- Testing
- Japanese Encephalitis purified inactivated vaccine (IC51)
- Volunteers
- 2,675 people, healthy volunteers welcome
- Sponsor
- Valneva Austria GmbH
Dengue, Chikungunya
Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health Perspective
RACSMEI addresses the high burden of infectious diseases in low- and middle-income countries, including Cambodia, where limited surveillance and laboratory capacity often obscure etiologies and transmission dynamics.
- Conditions
- Dengue, Chikungunya, Zika Virus Infection, Japanese Encephalitis
- Trial name
- RACSMEI (NCT07358910)
- Where
- Cambodia
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- Institut Pasteur du Cambodge